Can In-Licensing Models Substitute for Discovery?

Has a new biotech business model emerged for pure drug development companies, which start as corporate shells with top flight management teams and then proceed to in-license and further develop multiple products? While the business model is not new, clearly drug development is more fashionable today than drug discovery within the institutional investor community. The real question is whether the in-licensing model works any better than discovery.

Question: Has a new biotech business model emerged for pure drug development companies, which start as corporate shells with top flight management teams and then proceed to in-license and further develop multiple products?

Answer: While the business model is not new, clearly drug development is more fashionable today than drug discovery within the institutional investor community. The business model of in-licensing compromised, development-stage...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business